长期阿片类药物使用与慢性疼痛患者癌症风险的关联:倾向评分匹配队列研究
该研究基于台湾全民健康保险研究数据库2008年至2019年数据,采用倾向评分匹配按4:1比例比较使用与未使用阿片类药物的慢性疼痛患者的癌症发病率。匹配后共纳入63 610例患者,阿片组50 888例,非阿片组12 722例。多变量Cox回归分析显示,阿片组癌症调整风险比为2.66(95%CI 1.44-2.94;P<0.001),多种特定癌症发病率比值升高。结论认为长期阿片使用与慢性疼痛患者癌症发生存在关联,需未来研究确认。
要点
- 长期阿片使用与慢性疼痛患者癌症发生存在关联,调整HR为2.66。
- 肺癌、肝癌、结直肠癌、乳腺癌、前列腺癌等特定癌症发病率比值升高。
- 该关联为观察性发现,尚不能确定因果关系,需未来研究确认。
核心结论
- 长期阿片使用与慢性疼痛患者癌症发生存在关联,但需未来研究确认。
研究设计与样本
- 基于台湾全民健康保险研究数据库2008年1月至2019年12月数据的倾向评分匹配人群队列研究。
- 按有无阿片使用分组,以4:1比例匹配,最终纳入63 610例患者(阿片组50 888例,非阿片组12 722例)。
主要发现
- 多变量Cox回归分析中,阿片组相比非阿片组的癌症调整风险比为2.66(95%CI 1.44-2.94;P<0.001)。
- 肺癌发病率比值为1.87(95%CI 1.41-2.43),肝癌为1.97(95%CI 1.56-2.50),结直肠癌为2.39(95%CI 1.87-3.03)。
- 乳腺癌发病率比值为2.43(95%CI 1.75-3.33),前列腺癌为2.00(95%CI 1.35-3.03),头颈癌为1.79(95%CI 1.14-2.86)。
- 胰腺癌发病率比值为1.87(95%CI 1.13-2.12),胃癌为2.43(95%CI 1.52-3.85),食管癌为1.82(95%CI 0.92-3.70),卵巢癌为2.33(95%CI 1.01-5.55)。
临床怎么用
- 对慢性疼痛患者长期使用阿片类药物时,应关注潜在癌症风险并纳入随访评估。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether long-term opioid use is an independent risk factor for cancer progression remains unclear. Therefore, we conducted a propensity score-matched population-based cohort study to compare cancer incidence between patients with chronic pain with and without opioid use. METHODS: Data from January 2008 to December 2019 were obtained from the Taiwan National Health Insurance Research Database. Patients were categorised into two groups according to the presence or absence of opioid use, and matched at a 4:1 ratio. The incidence rate ratios for specific cancers were determined. RESULTS: Propensity score-matching yielded 63 610 patients: 50 888 with opioid use (the opioid group) and 12 722 without (the non-opioid group). In a multivariate Cox regression analysis, the adjusted hazard ratio (95% confidence interval) for cancers in the opioid group compared with the non-opioid group was 2.66 (1.44-2.94; P<0.001). The incidence rate ratios (95% confidence interval) for lung, hepatocellular, colorectal, breast, prostate, head and neck, pancreatic, gastric, oesophageal, and ovarian cancers for the opioid group were 1.87 (1.41-2.43), 1.97 (1.56-2.50), 2.39 (1.87-3.03), 2.43 (1.75-3.33), 2.00 (1.35-3.03), 1.79 (1.14-2.86), 1.87 (1.13-2.12), 2.43 (1.52-3.85), 1.82 (0.92-3.70), and 2.33 (1.01-5.55), respectively. CONCLUSION: There was an association between long-term opioid use and development of cancer in patients with chronic pain, which should be confirmed in future studies.
引用
- Sun M, Lin JA, Chang CL, et al. Association between long-term opioid use and cancer risk in patients with chronic pain: a propensity score-matched cohort study. Br J Anaesth. 2022. PMID: 35597621. doi:10.1016/j.bja.2022.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。